Thymosin β4 reduced brain cell death and neurological damage after stroke in rats by upregulating the protective protein GRP78 while suppressing pro-apoptotic CHOP and caspase-12.
Reduced neuronal apoptosisTβ4 significantly decreased brain cell death and neurological deficits in a rat stroke model vs. untreated controls
What the researchers found
In 48 rats divided into sham, ischemia/reperfusion (I/R), and Tβ4 treatment groups (n=16 each):
- Tβ4-treated rats had significantly lower Zea-Longa neurological deficit scores compared to I/R controls
- Tβ4 significantly reduced neuronal apoptosis (TUNEL-positive cells) compared to I/R group
- Tβ4 significantly increased GRP78 expression (a protective endoplasmic reticulum chaperone)
- Tβ4 significantly decreased CHOP and caspase-12 expression (pro-apoptotic ER stress markers)
- These changes indicate Tβ4 protects neurons by modulating the endoplasmic reticulum stress response pathway
Why it matters
Stroke is a leading cause of death and disability worldwide, and current treatments have narrow time windows. Thymosin β4's ability to reduce brain damage after ischemia/reperfusion injury through the ER stress pathway could lead to a neuroprotective treatment that extends the therapeutic window for stroke patients.
How the study worked
Forty-eight Sprague-Dawley rats were divided into three groups. Focal cerebral ischemia/reperfusion was induced by blocking the right middle cerebral artery for 2 hours followed by 24 hours of reperfusion. Neurological deficits were scored, infarct volume was measured by TTC staining, apoptosis was detected by TUNEL assay, and GRP78, CHOP, and caspase-12 protein levels were assessed by immunohistochemistry and Western blot.
What this study cannot tell us
The study used a standard rat stroke model which may not fully replicate human stroke complexity. Only 24-hour reperfusion was assessed — longer-term outcomes are unknown. The dose and timing of Tβ4 administration weren't detailed in the abstract. No behavioral or cognitive recovery testing beyond neurological deficit scoring was performed. No human clinical trials for Tβ4 in stroke exist.
How to read the evidence
Preclinical rat study with appropriate group sizes (n=16 per group) and multiple complementary outcome measures. While the mechanistic evidence is solid, all findings are in rats with no human stroke data for Tβ4.
When this study was published
Published in 2019 in Molecular Medicine Reports. Thymosin β4 neuroprotection research has continued since, though clinical translation for stroke has not yet occurred.
The bigger picture
Thymosin β4 continues to demonstrate protective effects across multiple organ systems — from heart to brain to skin. This study adds stroke neuroprotection to its portfolio, working through a specific molecular mechanism (ER stress modulation) that's distinct from its known effects on wound healing and cardiac repair.
Questions still open
- What is the therapeutic time window for Tβ4 administration after stroke onset?
- Could Tβ4 be combined with existing stroke treatments (tPA, thrombectomy) for additive neuroprotection?
- Does Tβ4's neuroprotective mechanism through ER stress modulation apply to other neurodegenerative conditions?
Common questions
How does Thymosin β4 protect the brain after stroke?
Could Thymosin β4 be used to treat stroke in humans?
Read the original research
Effects of thymosin β4 on neuronal apoptosis in a rat model of cerebral ischemia‑reperfusion injury.
Molecular medicine reports, 20(5), 4186-4192
Citation
Zhang, Zhongsheng; Liu, Shuangfeng; Huang, Sichun. (2019). Effects of thymosin β4 on neuronal apoptosis in a rat model of cerebral ischemia‑reperfusion injury.. Molecular medicine reports, 20(5), 4186-4192. https://doi.org/10.3892/mmr.2019.10683